Profusa, Inc. Common Stock (PFSA) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Profusa Inc (PFSA) 3-Minute Overview > **💡 One-Sentence Summary** > > Simply put, Profusa is a tiny early-stage digital health company trying to build continuous biochemical and oxygen-monitoring technology, and right now the stock is trading more on future promises and deal headlines than on proven financial results. > **📍 Basic Profile** > > Market Cap **$0.001 billion** · Health Care · NASDAQ NMS - GLOBAL MARKET · Price **$1.85** > **⚡ 3 Things You Should Know** > > 1. 📈 Story stock, not earnings stock: PFSA just surged more than 140% in a day after announcing a proposed $30M PanOmics deal, which tells you the market is reacting to strategic headlines rather than operating performance. In other words, sentiment can move this name fast in both directions. > > 2. ⚠️ Liquidity looks very tight: The current ratio is just 0.18 and quick ratio is near zero, which usually means near-term funding flexibility is weak. Basically, even if the technology story is interesting, the balance sheet leaves little room for mistakes. > > 3. 🧪 Commercial traction is still early: Recent purchase orders, a raised 2026 revenue outlook, and a Mayo Clinic collaboration are encouraging signs, but they still sit on a very small revenue base. So the real question is whether these partnerships turn into repeatable sales, not just press releases. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | ROE -22.12%, ROA -103.81%, no positive earnings data provided | > | Growth Rate | Medium✋ | Recent guidance improved, but 3-year growth data unavailable | > | Financial Health | Tight🧡 | Current ratio 0.18, quick ratio 0.00, debt/equity 0.16 | > | Valuation | [Data unavailable] | PE unavailable; stock appears driven by speculation and news flow | --- ## 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Profusa develops digital health and monitoring technology for medical and diagnostic applications, aiming to make money through product sales, platform commercialization, and potentially partnerships in precision diagnostics. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Oxygen monitoring / Lumee platform | [Data unavailable] | ↑ | Recent purchase orders suggest early commercialization is starting | | Precision diagnostics / PanOmics expansion | [Data unavailable] | ↑ | Proposed acquisition could broaden the platform, but deal execution is still pending | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | [Data unavailable] | [Data unavailable] | No margin data provided, which makes unit economics hard to judge | | Net Margin | [Data unavailable] | [Data unavailable] | Lack of earnings support suggests the company is still not operating at scale | | ROE | -22.12% | Below Average | Negative shareholder returns are typical for an early-stage company, but still a red flag | --- #### 📈 How's the Growth? **Growth Assessment:** High potential, but still unproven | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > What's interesting is that the recent growth narrative seems to be coming from commercial milestones—purchase orders, raised 2026 revenue guidance, and the Mayo collaboration—rather than a long record of reported financial growth. That usually means upside could be meaningful if adoption sticks, but it also means expectations can get ahead of reality very quickly. --- #### 💰 Financial Health Check **One Sentence:** This looks like a company with a promising idea but a very thin wallet—light debt, but near-term liquidity is the bigger problem. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 16.3% | <60% safe | ✅Safe | | Current Ratio | 0.18 | >1.5 healthy | 🚨Dangerous | | Cash Flow | [Data unavailable] | >0 | [Data unavailable] | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $0.41 - 52-Week High: $957.00 - Current: $1.85, Near the low | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(0.15% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE [Data unavailable] | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the market is not pricing PFSA on current earnings at all. It's betting that the company's monitoring technology, Mayo collaboration, and planned diagnostics expansion can eventually turn into a real commercial platform. If that commercialization stalls, the stock has very little fundamental support. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-04-06 | Signed LOI for a $30M PanOmics platform acquisition targeting precision diagnostics | Positive + Expanded the story into a larger addressable market and triggered a sharp stock rally | | 2026-02-27 | Withdrew S-1 to pursue a smaller, more focused offering | Mixed + Less immediate dilution pressure, but also highlights ongoing capital planning sensitivity | | 2026-02-19 | Received Lumee purchase orders and raised 2026 revenue guidance to $1.5M-$3.0M | Positive + Suggests real customer interest, though the revenue base remains small | | 2026-02-13 | Entered collaboration with Mayo Clinic on oxygen monitoring applications | Positive + Adds credibility and may help regulatory and commercial progress | --- ## 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -22.12% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | [Most Recent] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | | | | | | | | | | | | | | | **Earnings Trend Interpretation:** There is no earnings history provided here, which is important because it limits how confidently we can judge execution. For a stock this speculative, missing earnings visibility is a big deal—not a small detail. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 0 firms | 0% | | Hold | 0 firms | 0% | | Sell | 0 firms | 0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net mixed/primarily administrative share movements in past 3 months > Worth noting: the insider transactions shown are mostly coded as "J" and one "A", which often means non-open-market or automatic/administrative adjustments rather than executives actively buying shares with cash in the open market. So I wouldn't read this as a strong insider conviction signal. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Funding Risk:** Liquidity is extremely weak based on the current and quick ratios → If financing is needed soon, it could lead to dilution or tighter operating flexibility 2. **Execution Risk:** The company is trying to convert collaborations, purchase orders, and a proposed acquisition into a scalable business → If commercialization slips, the growth story could unwind fast 3. **Volatility Risk:** A 140%+ one-day move shows this stock can behave like a headline-driven micro-cap → If sentiment turns, price swings could be severe regardless of fundamentals --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Profusa is a micro-cap digital health company building continuous monitoring and diagnostics technology, still very early in its commercial journey. > > **Key strength:** The interesting part is that it now has several credibility-building catalysts at once—purchase orders, higher guidance, a Mayo Clinic collaboration, and a planned expansion into precision diagnostics. > > **Key risk:** The biggest concern is simple: the balance sheet looks tight, profits are absent, and the stock is moving on narrative more than financial proof. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis